PMID- 21371173
OWN - NLM
STAT- MEDLINE
DCOM- 20110720
LR  - 20181201
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 102
IP  - 6
DP  - 2011 Jun
TI  - Immunogenic enhancement and clinical effect by type-I interferon of 
      anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal 
      cancer patients.
PG  - 1181-7
LID - 10.1111/j.1349-7006.2011.01918.x [doi]
AB  - We previously identified a human leukocyte antigen (HLA)-A24-restricted antigenic 
      peptide, survivin-2B80-88, recognized by CD8+ cytotoxic T lymphocytes (CTL). 
      Subsequently, we attempted clinical trials with this epitope peptide alone for 
      some malignancies, resulting in clinical and immunological responses, although 
      their potential was not strong enough for routine clinical use as a cancer 
      vaccine. In the current study, to assess whether immunogenicity of the 
      survivin-2B80-88 peptide could be enhanced with other vaccination protocols, we 
      performed clinical trials in advanced colon cancer patients with two vaccination 
      protocols: (i) survivin-2B80-88 plus incomplete Freund's adjuvant (IFA); and (ii) 
      survivin-2B80-88 plus IFA and a type-I interferon (IFN), IFNalpha. Our data clearly 
      indicated that, although the effect of survivin-2B80-88 plus IFA was not 
      significantly different from that with survivin-2B80-88 alone, treatment with the 
      vaccination protocol of survivin-2B80-88 plus IFA and IFNalpha resulted in clinical 
      improvement and enhanced immunological responses of patients. Tetramer analysis 
      of survivin-2B80-88 peptide-specific CTL demonstrated that such CTL were 
      increased at least twofold after vaccination with this protocol in four of eight 
      patients. In these patients, enzyme-linked immunosorbent spot (ELISPOT) results 
      were also enhanced. Subsequent study of single-cell clone separation by cell 
      sorting of peptide-specific CTL showed that each CTL clone was indeed not only 
      peptide-specific but also cytotoxic against human cancer cells in the context of 
      the expression of both HLA-A24 and survivin molecules. Taken together, these 
      results indicate that vaccination of colon cancer patients with survivin-2B80-88 
      plus IFA and IFNalpha can be considered to be a very potent immunotherapeutic 
      regimen, and that this protocol might work for other cancers.
CI  - (c) 2011 Japanese Cancer Association.
FAU - Kameshima, Hidekazu
AU  - Kameshima H
AD  - Departments of Surgery Pathology, Sapporo Medical University School of Medicine, 
      Sapporo, Japan.
FAU - Tsuruma, Tetsuhiro
AU  - Tsuruma T
FAU - Torigoe, Toshihiko
AU  - Torigoe T
FAU - Takahashi, Akari
AU  - Takahashi A
FAU - Hirohashi, Yoshihiko
AU  - Hirohashi Y
FAU - Tamura, Yasuaki
AU  - Tamura Y
FAU - Tsukahara, Tomohide
AU  - Tsukahara T
FAU - Ichimiya, Shingo
AU  - Ichimiya S
FAU - Kanaseki, Takayuki
AU  - Kanaseki T
FAU - Iwayama, Yuji
AU  - Iwayama Y
FAU - Sato, Noriyuki
AU  - Sato N
FAU - Hirata, Koichi
AU  - Hirata K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110424
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (Interferon Type I)
RN  - 0 (Peptide Fragments)
RN  - 0 (Survivin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Cancer Vaccines/administration & dosage/*immunology
MH  - Colorectal Neoplasms/*immunology/*therapy
MH  - Enzyme-Linked Immunospot Assay
MH  - Female
MH  - HLA-A Antigens/immunology
MH  - HLA-A24 Antigen
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/administration & dosage/*immunology
MH  - Interferon Type I/administration & dosage/*immunology
MH  - Male
MH  - Middle Aged
MH  - Peptide Fragments/administration & dosage/*immunology
MH  - Survivin
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Treatment Outcome
EDAT- 2011/03/05 06:00
MHDA- 2011/07/21 06:00
CRDT- 2011/03/05 06:00
PHST- 2011/03/05 06:00 [entrez]
PHST- 2011/03/05 06:00 [pubmed]
PHST- 2011/07/21 06:00 [medline]
AID - 10.1111/j.1349-7006.2011.01918.x [doi]
PST - ppublish
SO  - Cancer Sci. 2011 Jun;102(6):1181-7. doi: 10.1111/j.1349-7006.2011.01918.x. Epub 
      2011 Apr 24.